Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CYTOKINETICS INCCYTK · Entity 3528 | Director | July 15, 2026 | July 16, 2026 |
| Sarepta Therapeutics, Inc.SRPT · Entity 4426 | Director | August 03, 2017 | August 07, 2017 |
| Stoke Therapeutics, Inc.STOK · Entity 1723 | Director | August 14, 2026 | August 19, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CYTOKINETICS INC
Report date July 15, 2026 · Filed July 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 10,434 |
Reported balance
After 2026-07-15 transaction · row 1
1 source rowRow 1 · 2026-07-15 · Grant · Acquired 151 · Balance 10,434 F1: Shares of common stock granted pursuant to the Cytokinetics Equity in lieu of Cash Retainer Program. Shares are fully vested at the time of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares of common stock granted pursuant to the Cytokinetics Equity in lieu of Cash Retainer Program. Shares are fully vested at the time of grant.
Sarepta Therapeutics, Inc.
Report date August 03, 2017 · Filed August 07, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 71,229 |
Ending reported balance
After 2017-08-03 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2017-08-03 · Exercise / conversion · Acquired 35,461 · Balance 87,932 F1: Restricted stock units convert into common stock on a one-for-one basis. Row 2 · 2017-08-03 · Tax withholding · Disposed 16,703 · Balance 71,229 F2: Shares were withheld by the Company to satisfy tax withholding obligations related to a vesting of restricted stock units granted on March 3, 2017. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2017-08-03 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2017-08-03 · Exercise / conversion · Disposed 35,461 · Balance 0 F1: Restricted stock units convert into common stock on a one-for-one basis. F3: On March 3, 2017, the reporting person was granted restricted stock units that vest based on the Company's satisfaction of certain performance criteria. The first performance criterion was met on August 3, 2017, resulting in vesting of 50% of such restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock units convert into common stock on a one-for-one basis.
F2: Shares were withheld by the Company to satisfy tax withholding obligations related to a vesting of restricted stock units granted on March 3, 2017.
F3: On March 3, 2017, the reporting person was granted restricted stock units that vest based on the Company's satisfaction of certain performance criteria. The first performance criterion was met on August 3, 2017, resulting in vesting of 50% of such restricted stock units.
Stoke Therapeutics, Inc.
Report date August 14, 2026 · Filed August 19, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 124,557 |
Ending reported balance
After 2026-08-18 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2026-08-14 · Exercise / conversion · Acquired 26,250 · Balance 137,124 Row 2 · 2026-08-18 · Sale · Disposed 11,930 · Balance 125,194 F1: The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units. F2: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.40 to $32.36 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 3 of this Form 4. Row 3 · 2026-08-18 · Sale · Disposed 637 · Balance 124,557 F1: The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units. F3: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.44 to $32.54 per share, inclusive. |
| Performance Stock UnitsSEC Table II · derivative / convertible security · Expires 2026-08-14 | Direct | 0 |
Reported balance
After 2026-08-14 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-08-14 · Exercise / conversion · Disposed 26,250 · Balance 0 F4: Each performance stock unit represents a right to receive one share of the Issuer's common stock. F5: Achievement of this performance stock unit award was certified on August 14, 2025. Pursuant to the terms of the award agreement between the reporting person and the Issuer, half the award vested on August 14, 2025 and the remainder vests on August 14, 2026, subject to the reporting person's continued service to the Issuer on the relevant vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units.
F2: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.40 to $32.36 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 3 of this Form 4.
F3: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.44 to $32.54 per share, inclusive.
F4: Each performance stock unit represents a right to receive one share of the Issuer's common stock.
F5: Achievement of this performance stock unit award was certified on August 14, 2025. Pursuant to the terms of the award agreement between the reporting person and the Issuer, half the award vested on August 14, 2025 and the remainder vests on August 14, 2026, subject to the reporting person's continued service to the Issuer on the relevant vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Avidity Biosciences, Inc.
Report date February 27, 2026 · Filed February 27, 2026
Section 16 reporting ended · disclosed 2026-02-27. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-02-27 transaction · row 1
1 source rowRow 1 · 2026-02-27 · Disposition to issuer · Disposed 6,692 · Balance 0 F1: The reported securities represent shares of Common Stock (inclusive of shares of Common Stock issuable upon settlement of previously reported restricted stock units) disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of October 25, 2025 (the "Merger Agreement"), among Novartis AG ("Novartis"), Ajax Acquisition Sub, Inc., an indirect wholly owned subsidiary of Novartis, and the Issuer. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $33.62 · Expires 2035-06-09 | Direct | 0 |
Reported balance
After 2026-02-27 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-02-27 · Disposition to issuer · Disposed 10,034 · Balance 0 F2: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $39.96 · Expires 2034-06-12 | Direct | 0 |
Reported balance
After 2026-02-27 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-02-27 · Disposition to issuer · Disposed 13,489 · Balance 0 F2: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.48 · Expires 2033-06-14 | Direct | 0 |
Reported balance
After 2026-02-27 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-02-27 · Disposition to issuer · Disposed 22,000 · Balance 0 F2: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.03 · Expires 2032-06-14 | Direct | 0 |
Reported balance
After 2026-02-27 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-02-27 · Disposition to issuer · Disposed 22,000 · Balance 0 F2: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.09 · Expires 2031-06-15 | Direct | 0 |
Reported balance
After 2026-02-27 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-02-27 · Disposition to issuer · Disposed 15,000 · Balance 0 F2: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.82 · Expires 2030-05-14 | Direct | 0 |
Reported balance
After 2026-02-27 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-02-27 · Disposition to issuer · Disposed 11,323 · Balance 0 F2: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.42 · Expires 2029-08-27 | Direct | 0 |
Reported balance
After 2026-02-27 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-02-27 · Disposition to issuer · Disposed 9,534 · Balance 0 F2: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported securities represent shares of Common Stock (inclusive of shares of Common Stock issuable upon settlement of previously reported restricted stock units) disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of October 25, 2025 (the "Merger Agreement"), among Novartis AG ("Novartis"), Ajax Acquisition Sub, Inc., an indirect wholly owned subsidiary of Novartis, and the Issuer.
F2: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 05, 2020 Filed Oct 6, 2020 00:38 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $7.61 | $0.00 |
DisclosureSEC source: 0001061983-20-000161 · edgardoc.xml · derivative · entry 3 Kaye Edward M. MD · CIK 0001522780 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 20,000 shares Expires 2026-05-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction effected pursuant to a 10b5-1 plan entered into by the Reporting Person on May 13, 2020. Read SEC document |
| October 05, 2020 Filed Oct 6, 2020 00:38 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 20,000 | $30.00 | $600,000.00 |
DisclosureSEC source: 0001061983-20-000161 · edgardoc.xml · nonDerivative · entry 2 Kaye Edward M. MD · CIK 0001522780 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Transaction effected pursuant to a 10b5-1 plan entered into by the Reporting Person on May 13, 2020. Read SEC document |
| October 05, 2020 Filed Oct 6, 2020 00:38 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 20,000 | $7.61 | $152,200.00 |
DisclosureSEC source: 0001061983-20-000161 · edgardoc.xml · nonDerivative · entry 1 Kaye Edward M. MD · CIK 0001522780 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction effected pursuant to a 10b5-1 plan entered into by the Reporting Person on May 13, 2020. Read SEC document |
| May 13, 2020 Filed May 14, 2020 20:46 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 20,000 | $21.61 Strike: $21.61 | $432,200.00 |
DisclosureSEC source: 0001061983-20-000090 · edgardoc.xml · derivative · entry 1 Kaye Edward M. MD · CIK 0001522780 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2030-05-13 F1 · derivative.exercise_date: Options shall vest and become exercisable in 12 equal monthly installments as from the date of the grant. Read SEC document |
| March 25, 2020 Filed Mar 26, 2020 22:02 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | GrantEmployee Stock Option (Right to Buy) · Derivative | 197,000 | $0.00 Strike: $20.25 | $0.00 |
DisclosureSEC source: 0001209191-20-021314 · doc4.xml · derivative · entry 1 Kaye Edward M. MD · CIK 0001522780 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197,000 Underlying: Common Stock · 197,000 shares Expires 2030-03-24 F1 · derivative.exercise_date: The option vests as to 1/48th of the total shares on April 25, 2020 and then 1/48th of the total shares vest monthly thereafter, subject to reporting person's continued service to the issuer through each vesting date. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 22:40 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 8,248 | $15.43 Strike: $15.43 | $127,266.64 |
DisclosureSEC source: 0001061983-20-000031 · edgardoc.xml · derivative · entry 1 Kaye Edward M. MD · CIK 0001522780 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,248 Underlying: Common Stock · 8,248 shares Expires 2030-02-12 Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 23:55 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 1,517 | $10.55 Strike: $10.55 | $16,004.35 |
DisclosureSEC source: 0001061983-20-000011 · edgardoc.xml · derivative · entry 1 Kaye Edward M. MD · CIK 0001522780 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,517 Underlying: Common Stock · 1,517 shares Expires 2030-01-02 F1 · derivative.exercise_date: This option shall vest and become exercisable in 12 equal monthly installments and shall become fully vested on January 2, 2021. Read SEC document |
| January 02, 2020 Filed Jan 29, 2020 17:57 UTC Amendment | CYTOKINETICS INC CYTK · Entity 3528 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 9,479 | $10.55 Strike: $10.55 | $100,003.45 |
DisclosureSEC source: 0001061983-20-000021 · edgardoc.xml · derivative · entry 1 Kaye Edward M. MD · CIK 0001522780 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,479 Underlying: Common Stock · 9,479 shares Expires 2030-01-02 F1 · derivative.exercise_date: This option shall vest and become exercisable in 12 equal monthly installments and shall become fully vested on January 2, 2021. F2 · derivative.underlying_shares: This Form 4/A is being filed to report the correct number of shares underlying the stock option, which was granted to the reporting person in connection with his election to receive 100% of his non-employee director retainer in equity, pursuant to the methodology described in the Company's most recent Proxy Statement. The number of shares reported on the Form 4 filed January 6, 2020 was incorrect due to an administrative error. Read SEC document |
| December 16, 2019 Filed Apr 15, 2020 23:27 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0001209191-20-024543 · doc4.xml · derivative · entry 2 Kaye Edward M. MD · CIK 0001522780 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 647,801 Underlying: Common Stock · 50,000 shares Expires 2028-04-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option vested as to 1/4th of the total shares on October 17, 2018, and then 1/48th of the total shares vest monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
| December 16, 2019 Filed Apr 15, 2020 23:27 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionCommon Stock | 50,000 | $0.60 | $30,000.00 |
DisclosureSEC source: 0001209191-20-024543 · doc4.xml · nonDerivative · entry 1 Kaye Edward M. MD · CIK 0001522780 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 16, 2019 Filed May 26, 2020 21:54 UTC Amendment | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0001209191-20-032142 · doc4a.xml · derivative · entry 1 Kaye Edward M. MD · CIK 0001522780 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 647,801 Underlying: Common Stock · 50,000 shares Expires 2028-04-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option vested as to 1/4th of the total shares on October 17, 2018, and then 1/48th of the total shares vest monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
| May 15, 2019 Filed May 17, 2019 21:08 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 20,000 | $10.68 Strike: $10.68 | $213,600.00 |
DisclosureSEC source: 0001061983-19-000038 · edgardoc.xml · derivative · entry 1 Kaye Edward M. MD · CIK 0001522780 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2029-05-15 F1 · derivative.exercise_date: This option shall vest and become exercisable in 12 equal monthly installments and shall become fully vested on May 15, 2020 Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 23:49 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 6,414 | $6.82 Strike: $6.82 | $43,743.48 |
DisclosureSEC source: 0001061983-19-000005 · edgardoc.xml · derivative · entry 1 Kaye Edward M. MD · CIK 0001522780 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,414 Underlying: Common Stock · 6,414 shares Expires 2029-01-02 F1 · derivative.exercise_date: This option shall vest and become exercisable in 12 equal monthly installments and shall become fully vested on January 2, 2020. Read SEC document |
| May 16, 2018 Filed May 17, 2018 22:28 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 20,000 | $9.45 Strike: $9.45 | $189,000.00 |
DisclosureSEC source: 0001061983-18-000028 · edgardoc.xml · derivative · entry 1 Kaye Edward M. MD · CIK 0001522780 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2028-05-16 F1 · derivative.exercise_date: This option shall vest and become exercisable in 12 equal monthly installments and shall become fully vested on May 16, 2019 Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 23:36 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 11,428 | $3.50 Strike: $8.75 | $40,000.29 |
DisclosureSEC source: 0001061983-18-000003 · edgardoc.xml · derivative · entry 1 Kaye Edward M. MD · CIK 0001522780 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,428 Underlying: Common Stock · 11,428 shares Expires 2028-01-02 F2 · price: This option was issued to the reporting person pursuant to the Cytokinetics 2004 Equity Incentive Plan in lieu of an annual retainer of $40,000.00. F1 · derivative.exercise_date: This option shall vest and become exercisable as to 11,428 shares divided into equal monthly installments such that the option shall be 100% vested on January 2, 2019. Read SEC document |
| August 03, 2017 Filed Aug 7, 2017 20:39 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionRestricted Stock Units · Derivative | 35,461 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-047896 · doc4.xml · derivative · entry 3 Kaye Edward M. MD · CIK 0001522780 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 35,461 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: On March 3, 2017, the reporting person was granted restricted stock units that vest based on the Company's satisfaction of certain performance criteria. The first performance criterion was met on August 3, 2017, resulting in vesting of 50% of such restricted stock units. F3 · derivative.expiration_date: On March 3, 2017, the reporting person was granted restricted stock units that vest based on the Company's satisfaction of certain performance criteria. The first performance criterion was met on August 3, 2017, resulting in vesting of 50% of such restricted stock units. Read SEC document |
| August 03, 2017 Filed Aug 7, 2017 20:39 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Tax withholdingCommon Stock | 16,703 | $37.88 | $632,709.64 |
DisclosureSEC source: 0001209191-17-047896 · doc4.xml · nonDerivative · entry 2 Kaye Edward M. MD · CIK 0001522780 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,229 F2 · price: Shares were withheld by the Company to satisfy tax withholding obligations related to a vesting of restricted stock units granted on March 3, 2017. Read SEC document |
| August 03, 2017 Filed Aug 7, 2017 20:39 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 35,461 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-047896 · doc4.xml · nonDerivative · entry 1 Kaye Edward M. MD · CIK 0001522780 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,932 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| July 20, 2017 Filed Jul 22, 2017 01:48 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | SaleCommon Stock | 10,000 | $41.00 | $410,000.00 |
DisclosureSEC source: 0001209191-17-046038 · doc4.xml · nonDerivative · entry 2 Kaye Edward M. MD · CIK 0001522780 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,471 F2 · shares: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person, on May 12, 2017, accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| July 20, 2017 Filed Jul 22, 2017 01:48 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Tax withholdingCommon Stock | 4,349 | $40.93 | $178,004.57 |
DisclosureSEC source: 0001209191-17-046038 · doc4.xml · nonDerivative · entry 1 Kaye Edward M. MD · CIK 0001522780 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,471 F1 · shares: Shares were withheld by the Company to satisfy tax withholding obligations related to a vesting of restricted stock. Read SEC document |
| May 18, 2017 Filed May 22, 2017 21:56 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $14.25 | $0.00 |
DisclosureSEC source: 0001061983-17-000032 · edgardoc.xml · derivative · entry 1 Kaye Edward M. MD · CIK 0001522780 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2027-05-18 F1 · derivative.exercise_date: This option shall vest and become exercisable in 12 equal monthly installments and shall become fully vested on May 18, 2018. Read SEC document |
| April 20, 2017 Filed Apr 24, 2017 21:11 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Tax withholdingCommon Stock | 4,349 | $32.54 | $141,516.46 |
DisclosureSEC source: 0001209191-17-027998 · doc4.xml · nonDerivative · entry 1 Kaye Edward M. MD · CIK 0001522780 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,820 F1 · shares: Shares were withheld by the Company to satisfy tax withholding obligations related to a vesting of restricted stock. Read SEC document |
| March 10, 2017 Filed Mar 15, 2017 01:47 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantIncentive Stock Option (right to buy) · Derivative | 4,377 | $0.00 Strike: $32.63 | $0.00 |
DisclosureSEC source: 0001209191-17-020688 · doc4.xml · derivative · entry 2 Kaye Edward M. MD · CIK 0001522780 · Director · President, CEO & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,377 Underlying: Common Stock · 4,377 shares Expires 2027-03-10 F1 · derivative.exercise_date: 25% of the option granted vests and is exercisable on the first anniversary of the date of grant and 1/48th of the total granted option will vest and become exercisable on each monthly anniversary thereafter, such that the option will be fully vested and exercisable on the fourth anniversary of the date of grant. Read SEC document |
| March 10, 2017 Filed Mar 15, 2017 01:47 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 95,623 | $0.00 Strike: $32.63 | $0.00 |
DisclosureSEC source: 0001209191-17-020688 · doc4.xml · derivative · entry 1 Kaye Edward M. MD · CIK 0001522780 · Director · President, CEO & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,623 Underlying: Common Stock · 95,623 shares Expires 2027-03-10 F1 · derivative.exercise_date: 25% of the option granted vests and is exercisable on the first anniversary of the date of grant and 1/48th of the total granted option will vest and become exercisable on each monthly anniversary thereafter, such that the option will be fully vested and exercisable on the fourth anniversary of the date of grant. Read SEC document |
| January 20, 2017 Filed Jan 24, 2017 22:52 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Tax withholdingCommon Stock | 4,466 | $32.66 | $145,859.56 |
DisclosureSEC source: 0001209191-17-005349 · doc4.xml · nonDerivative · entry 1 Kaye Edward M. MD · CIK 0001522780 · Director · President, CEO & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,169 F1 · shares: Shares were withheld by the Company to satisfy tax withholding obligations related to a vesting of restricted stock. Read SEC document |
| January 03, 2017 Filed Jan 4, 2017 23:47 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 8,064 | $4.96 Strike: $12.40 | $39,999.86 |
DisclosureSEC source: 0001061983-17-000007 · edgardoc.xml · derivative · entry 1 Kaye Edward M. MD · CIK 0001522780 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,064 Underlying: Common Stock · 8,064 shares Expires 2027-01-03 F2 · price: This option was issued to the reporting person pursuant to the Cytokinetics 2004 Equity Incentive Plan in lieu of an annual retainer of $40,000.00 F1 · derivative.exercise_date: This option shall vest and become exercisable as to 8,064 shares divided into equal monthly installments such that the option shall be 100% vested on January 3, 2018. Read SEC document |
| November 09, 2016 Filed Nov 10, 2016 13:19 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 3,000 | $0.00 Strike: $8.28 | $0.00 |
DisclosureSEC source: 0001209191-16-149227 · doc4.xml · derivative · entry 2 Kaye Edward M. MD · CIK 0001522780 · Director · President, CEO & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,309 Underlying: Common Stock · 3,000 shares Expires 2021-06-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option became exercisable at the rate of 25% of the shares on June 20, 2012 and 1/48th of the total granted shares on each monthly anniversary thereafter, such that the option became fully exercisable on June 20, 2015. Read SEC document |
| November 09, 2016 Filed Nov 10, 2016 13:19 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 3,000 | $8.28 | $24,840.00 |
DisclosureSEC source: 0001209191-16-149227 · doc4.xml · nonDerivative · entry 1 Kaye Edward M. MD · CIK 0001522780 · Director · President, CEO & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,635 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 20, 2016 Filed Oct 24, 2016 20:33 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Tax withholdingCommon Stock | 4,348 | $49.05 | $213,269.40 |
DisclosureSEC source: 0001209191-16-146739 · doc4.xml · nonDerivative · entry 1 Kaye Edward M. MD · CIK 0001522780 · Director · President, CEO & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,635 F1 · shares: Shares were withheld by the Company to satisfy tax withholding obligations related to a vesting of restricted stock. Read SEC document |
| September 22, 2016 Filed Sep 26, 2016 20:23 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionNon-Qualified Stock Options (right to buy) · Derivative | 40,179 | $8.28 Strike: $13.90 | $332,682.12 |
DisclosureSEC source: 0001209191-16-142786 · doc4.xml · derivative · entry 3 Kaye Edward M. MD · CIK 0001522780 · Director · President, CEO & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,179 Underlying: Common Stock · 40,179 shares Expires 2021-06-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person, on March 16, 2016, accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| September 22, 2016 Filed Sep 26, 2016 20:23 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | SaleCommon Stock | 40,179 | $60.00 | $2,410,740.00 |
DisclosureSEC source: 0001209191-16-142786 · doc4.xml · nonDerivative · entry 2 Kaye Edward M. MD · CIK 0001522780 · Director · President, CEO & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,983 F1 · shares: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person, on March 16, 2016, accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| September 22, 2016 Filed Sep 26, 2016 20:23 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 40,179 | $8.28 | $332,682.12 |
DisclosureSEC source: 0001209191-16-142786 · doc4.xml · nonDerivative · entry 1 Kaye Edward M. MD · CIK 0001522780 · Director · President, CEO & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,162 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person, on March 16, 2016, accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| September 19, 2016 Filed Sep 22, 2016 01:29 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionNon-Qualified Stock Options (right to buy) · Derivative | 10,405 | $5.40 Strike: $5.40 | $56,187.00 |
DisclosureSEC source: 0001209191-16-142357 · doc4.xml · derivative · entry 9 Kaye Edward M. MD · CIK 0001522780 · Director · President, CEO & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,405 shares Expires 2022-04-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person, on March 16, 2016, accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| September 19, 2016 Filed Sep 22, 2016 01:29 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionIncentive Stock Options (right to buy) · Derivative | 947 | $5.40 Strike: $5.40 | $5,113.80 |
DisclosureSEC source: 0001209191-16-142357 · doc4.xml · derivative · entry 8 Kaye Edward M. MD · CIK 0001522780 · Director · President, CEO & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 947 shares Expires 2022-04-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person, on March 16, 2016, accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| September 19, 2016 Filed Sep 22, 2016 01:29 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionNon-Qualified Stock Options (right to buy) · Derivative | 13,000 | $8.28 Strike: $13.90 | $107,640.00 |
DisclosureSEC source: 0001209191-16-142357 · doc4.xml · derivative · entry 7 Kaye Edward M. MD · CIK 0001522780 · Director · President, CEO & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,358 Underlying: Common Stock · 13,000 shares Expires 2012-06-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person, on March 16, 2016, accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| September 19, 2016 Filed Sep 22, 2016 01:29 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | SaleCommon Stock | 10,405 | $50.00 | $520,250.00 |
DisclosureSEC source: 0001209191-16-142357 · doc4.xml · nonDerivative · entry 6 Kaye Edward M. MD · CIK 0001522780 · Director · President, CEO & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,983 F1 · shares: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person, on March 16, 2016, accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| September 19, 2016 Filed Sep 22, 2016 01:29 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 10,405 | $5.40 | $56,187.00 |
DisclosureSEC source: 0001209191-16-142357 · doc4.xml · nonDerivative · entry 5 Kaye Edward M. MD · CIK 0001522780 · Director · President, CEO & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,388 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person, on March 16, 2016, accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| September 19, 2016 Filed Sep 22, 2016 01:29 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | SaleCommon Stock | 947 | $50.00 | $47,350.00 |
DisclosureSEC source: 0001209191-16-142357 · doc4.xml · nonDerivative · entry 4 Kaye Edward M. MD · CIK 0001522780 · Director · President, CEO & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,983 F1 · shares: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person, on March 16, 2016, accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| September 19, 2016 Filed Sep 22, 2016 01:29 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 947 | $5.40 | $5,113.80 |
DisclosureSEC source: 0001209191-16-142357 · doc4.xml · nonDerivative · entry 3 Kaye Edward M. MD · CIK 0001522780 · Director · President, CEO & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,930 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person, on March 16, 2016, accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| September 19, 2016 Filed Sep 22, 2016 01:29 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | SaleCommon Stock | 13,000 | $50.00 | $650,000.00 |
DisclosureSEC source: 0001209191-16-142357 · doc4.xml · nonDerivative · entry 2 Kaye Edward M. MD · CIK 0001522780 · Director · President, CEO & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,983 F1 · shares: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person, on March 16, 2016, accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| September 19, 2016 Filed Sep 22, 2016 01:29 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 13,000 | $8.28 | $107,640.00 |
DisclosureSEC source: 0001209191-16-142357 · doc4.xml · nonDerivative · entry 1 Kaye Edward M. MD · CIK 0001522780 · Director · President, CEO & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,983 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person, on March 16, 2016, accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| September 14, 2016 Filed Sep 16, 2016 20:04 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | SaleCommon Stock | 24,557 | $30.00 | $736,710.00 |
DisclosureSEC source: 0001209191-16-141771 · doc4.xml · nonDerivative · entry 1 Kaye Edward M. MD · CIK 0001522780 · SVP Interim CEO & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,983 F1 · shares: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person, on March 16, 2016, accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.